GLP-1 Calculator🇺🇸

Use this GLP-1 calculator master page to choose the right GLP-1 calculator for broad planning intent, including weight-loss projection, medication comparison.

Health estimate

Editorial responsibility: Calcipedia editorial team

This page is maintained against the site trust model for its topic and updated when formulas, sources, or guidance materially change.

Reviewed 2 May 2026 Updated 2 May 2026 Contact editorial team

GLP-1 calculator suite Use this master GLP-1 calculator page to move from eligibility screening to medication comparison, weight-loss projection, weight-loss-rate safety checks, dose timing, washout planning, protein targets, and US cost review in one place.

Plan the whole GLP-1 conversation, not just one number

These tools are designed for people comparing Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Rybelsus, semaglutide, and tirzepatide. They help organise questions for a licensed clinician: whether label criteria may fit, how brands differ, what trial-average weight change can look like, whether the current pace is concerning, how titration and washout timing work, how protein needs change during appetite suppression, and how US pricing scenarios compare.

Not medical advice; use current source review Source review date: 2026-05-02. No named medical reviewer has approved redirect consolidation, so the specialist GLP-1 calculators remain live. GLP-1 and GIP/GLP-1 prescribing decisions require a clinician who can review diagnosis, pregnancy status, pancreatitis or gallbladder history, thyroid cancer contraindications, diabetes medicines, kidney risk, side effects, and current product labels. Drug indications, shortages, prices, and insurance rules change, so check the latest FDA label, manufacturer prescribing information, pharmacy quote, and clinician guidance before acting on any result here.

Specialist GLP-1 calculators

GLP-1 eligibility calculator GLP-1 medication comparison calculator GLP-1 weight loss calculator GLP-1 weight loss rate calculator GLP-1 dose schedule calculator GLP-1 half-life calculator GLP-1 protein calculator GLP-1 cost calculator

Medication comparison calculator

GLP-1 planning comparison Compare the major GLP-1 and GIP/GLP-1 brands on label status, route, titration pace, and mean trial weight-change signal, including the diabetes-treatment versus weight-management label context people often compare in the same search session.

Comparison lens

Comparison horizon Route preference Reference body weight

Weight-unit shortcut

Spotlight medication

This planner keeps all major brands visible even when the chosen lens makes some of them off-label or less route-compatible. The goal is to surface the trade-offs clearly, not to make a prescribing decision for you.

How to read this sheet

Rows stay visible even when they are not on-label for weight management because many users compare Ozempic and Mounjaro against Wegovy or Zepbound before verifying the actual prescribing path with a clinician.

Route note

Any-route mode leaves the table ordered mostly by label fit and expected average weight-loss signal at the chosen horizon.

Scope

This planner translates published pivotal-trial averages into a side-by-side planning sheet. It is useful for structured comparison, but it does not individualise efficacy, side effects, insurance coverage, contraindications, or clinician-specific dose decisions.

Most aligned with your filters

Zepbound

On-label for weight management · Weekly injection

At 12 months, the published reference programme for Zepbound suggests about 19.3% average weight loss, or roughly 42.46 lb / 19.26 kg from your 220 lb reference body weight.

Weight-label routes

brands in the current comparison table

Diabetes-label routes

brands with a diabetes-labelled pathway

Weekly options

once-weekly injection rows in this model

Oral options

daily tablet row captured separately here

Strongest weight-loss signal in this table

Zepbound

19.3% at 12 months from the reference programme.

Direct head-to-head context

Direct obesity head-to-head evidence now exists for tirzepatide versus semaglutide. In SURMOUNT-5, adults with obesity or overweight without diabetes lost about 20.2% on tirzepatide versus 13.7% on semaglutide over 72 weeks. This planner still keeps the broader brand table visible, but that weekly Zepbound-versus-Wegovy comparison is now stronger than a pure cross-trial guess when you are using the 12 months lens.

Newer formulation watch

This table still ranks the weekly Wegovy evidence track and the diabetes-label oral semaglutide track separately. Newer Wegovy tablet and Wegovy HD pathways, plus newer non-weight indications such as MASH, cardiovascular-risk reduction, CKD-risk reduction, or OSA improvements, matter in real prescribing but are not all modelled as separate rows here.

Side-by-side comparison sheet

Rows are sorted by label fit, route fit, and the mean weight-loss signal at the selected horizon. Use the estimated loss columns as planning ranges, not as guarantees of personal response.

Brand	Route and label fit	12 months signal	Titration	Trial context
Zepbound tirzepatide 5–15 mg Reference formulation: weekly tirzepatide injection	On-label for weight management Any route Weight-management label and obstructive-sleep-apnea label	19.3% about 42.46 lb / 19.26 kg lost Estimated post-loss weight: 177.54 lb / 80.53 kg	15 mg (max/maintenance) Weekly · maintenance reached in about 20 weeks 6 titration steps · half-life about 5 days	SURMOUNT-1 (Jastreboff et al., NEJM 2022) — 15 mg arm Dual GIP/GLP-1 agonist with the strongest obesity-trial weight-loss averages in this dataset. OSA approval is separate from the weight-loss label.
Wegovy semaglutide 2.4 mg Reference formulation: weekly 2.4 mg pen	On-label for weight management Any route Weight-management label plus cardiovascular-risk reduction	13.8% about 30.36 lb / 13.77 kg lost Estimated post-loss weight: 189.64 lb / 86.02 kg	2.4 mg (maintenance) Weekly · maintenance reached in about 16 weeks 5 titration steps · half-life about 7 days	STEP 1 (Wilding et al., NEJM 2021) Uses obesity-label semaglutide data from the weekly-pen programme. Wegovy now also has a daily oral formulation, but that newer route is not modelled separately in this comparison table.
Saxenda liraglutide 3 mg Reference formulation: daily liraglutide injection	On-label for weight management Any route Weight-management label	8% about 17.6 lb / 7.98 kg lost Estimated post-loss weight: 202.4 lb / 91.81 kg	3 mg/day (maintenance) Daily · maintenance reached in about 4 weeks 5 titration steps · half-life about 0.54 days	SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015) Older daily-injection GLP-1 option that still matters for route and access comparisons, even though weekly agents are usually the main alternatives users are considering now.
Mounjaro tirzepatide 5–15 mg Reference formulation: weekly tirzepatide injection	Frequently compared, but off-label for weight loss Any route Type 2 diabetes label This brand is commonly discussed in weight-loss comparisons, but the label and trial population differ from obesity-label therapy.	12.5% about 27.5 lb / 12.47 kg lost Estimated post-loss weight: 192.5 lb / 87.32 kg	15 mg (max/maintenance) Weekly · maintenance reached in about 20 weeks 6 titration steps · half-life about 5 days	SURPASS-2 (Frías et al., NEJM 2021) — 15 mg arm vs semaglutide (T2D population) Same active molecule as Zepbound, but the weight-loss figures in this table come from a type 2 diabetes population rather than a dedicated obesity trial.
Ozempic semaglutide 0.5–2 mg Reference formulation: weekly semaglutide injection	Frequently compared, but off-label for weight loss Any route Type 2 diabetes label plus cardiovascular-risk reduction This brand is commonly discussed in weight-loss comparisons, but the label and trial population differ from obesity-label therapy.	5.3% about 11.66 lb / 5.29 kg lost Estimated post-loss weight: 208.34 lb / 94.5 kg	1 mg Weekly · maintenance reached in about 8 weeks 3 titration steps · half-life about 7 days	SUSTAIN 6 (Marso et al., NEJM 2016) — weight loss as secondary endpoint (T2D population) Shares semaglutide with Wegovy, but the labelled use, dose range, and study population differ. Weight-loss averages shown here come from diabetes-programme data.
Rybelsus oral semaglutide 14 mg Reference formulation: daily oral semaglutide tablet	Frequently compared, but off-label for weight loss Any route Type 2 diabetes label plus cardiovascular-risk reduction This brand is commonly discussed in weight-loss comparisons, but the label and trial population differ from obesity-label therapy.	4.2% about 9.24 lb / 4.19 kg lost Estimated post-loss weight: 210.76 lb / 95.6 kg	14 mg/day (maintenance) Daily · maintenance reached in about 8 weeks 3 titration steps · half-life about 7 days	PIONEER 6 (Husain et al., NEJM 2019) — at 14 mg (T2D population) Useful when an oral route matters most, but the percentages shown here come from the diabetes-label tablet programme rather than the newer oral Wegovy weight-loss formulation.

Dose pathway for Zepbound

The highest percentage shown here comes from the 15 mg SURMOUNT-1 arm. Lower maintenance doses can still be clinically appropriate and may produce smaller average losses.

Route

Weekly injection

Reference formulation: weekly tirzepatide injection

Label context

Weight-management label and obstructive-sleep-apnea label

Dual GIP/GLP-1 agonist with the strongest obesity-trial weight-loss averages in this dataset. OSA approval is separate from the weight-loss label.

Phase	Weeks	Dose	Frequency	Why it matters
Starting dose	Weeks 1-4	2.5 mg	Weekly	Starting dose, not for therapeutic effect
Dose step 5	Weeks 5-8	5 mg	Weekly	May be maintenance dose for some patients
Dose step 9	Weeks 9-12	7.5 mg	Weekly	Optional escalation
Dose step 13	Weeks 13-16	10 mg	Weekly	Optional escalation
Dose step 17	Weeks 17-20	12.5 mg	Weekly	Optional escalation
Ongoing maintenance	Week 21+	15 mg (max/maintenance)	Weekly	Standard label titration step

Comparison limits matter here The percentages shown are population averages from different trials, doses, and labelled uses. They are helpful for structured comparison, but they are not a promise of personal results and they should not replace clinician advice on the safest medication, dose, or route for you.

Weight-loss projection calculator

Use this GLP-1 weight loss calculator to compare trial-average results at 3, 6, 12, and 18 months for Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda. It turns published percentages into projected body weight at the same starting weight so you can compare trajectories instead of guessing from anecdotes.

What this page helps you compare Use the selector to compare semaglutide and tirzepatide trial averages on the same scale, then read the chart and comparison table to see how the same starting weight changes over time. This is a planning tool, not a prediction of your personal response.

Quick examples

Medication

Unit

Current weight (lbs) Height for BMI context (in)

Projection result

187.22 lbs

Wegovy at 18 months from a 220 lbs starting weight. Clinical trial averages. Roughly 50% of participants lose more than the median; about 15–20% are non-responders. Individual results depend on diet, activity, and adherence.

207.02 lbs

3 months

−12.98 lbs (5.9%)

197.34 lbs

6 months

−22.66 lbs (10.3%)

189.64 lbs

12 months

−30.36 lbs (13.8%)

187.22 lbs

18 months

−32.78 lbs (14.9%)

Projected BMI at 18 months

28.47

From 33.45 to 28.47 using the entered height.

BMI category band

25.0 to 29.9

BMI is only a screening context. It does not measure body composition, side effects, eligibility, or treatment suitability.

Projected weight trajectory

The chart shows the selected medicine's average trajectory at the same starting weight. It is a trial-average line, so the shape helps with planning but it does not predict your personal response.

How the major GLP-1 brands compare at the same starting weight

The table is sorted by 18-month average weight lost. Weight-management brands and diabetes-label comparators stay visible together so you can compare the evidence without treating every row as interchangeable.

Brand	Label context	Route	12 months	18 months
Zepbound tirzepatide 5–15 mg	Weight-management brand	Weekly injection	177.54 lbs −42.46 lbs (19.3%)	174.02 lbs −45.98 lbs (20.9%)
Wegovy semaglutide 2.4 mg	Weight-management brand	Weekly injection	189.64 lbs −30.36 lbs (13.8%)	187.22 lbs −32.78 lbs (14.9%)
Mounjaro tirzepatide 5–15 mg	Diabetes-label comparator	Weekly injection	192.5 lbs −27.5 lbs (12.5%)	190.74 lbs −29.26 lbs (13.3%)
Saxenda liraglutide 3 mg	Weight-management brand	Daily injection	202.4 lbs −17.6 lbs (8%)	202.84 lbs −17.16 lbs (7.8%)
Ozempic semaglutide 0.5–2 mg	Diabetes-label comparator	Weekly injection	208.34 lbs −11.66 lbs (5.3%)	207.02 lbs −12.98 lbs (5.9%)
Rybelsus oral semaglutide 14 mg	Diabetes-label comparator	Daily oral	210.76 lbs −9.24 lbs (4.2%)	210.76 lbs −9.24 lbs (4.2%)

Milestone planner for the selected medicine

Use the 5%, 10%, 15%, and 20% checkpoints to translate trial-average percentages into a rough calendar plan. If a row says not reached by 18 months, the medicine did not hit that milestone in the selected trial-average curve.

Milestone	Projected weight	Weight lost	Estimated month
5% milestone	209 lbs	−11 lbs	2.54 months
10% milestone	198 lbs	−22 lbs	5.8 months
15% milestone	187 lbs	−33 lbs	Not reached by 18 months
20% milestone	176 lbs	−44 lbs	Not reached by 18 months

How to read this result

A larger starting weight usually means a larger absolute number of pounds or kilograms lost for the same percentage, but the percentage itself is still the right way to compare the brands. If you are trying to decide between semaglutide and tirzepatide, use the chart and the table together.

Weight-loss rate safety calculator

Use this GLP-1 weight loss rate calculator to check whether your pace is too slow, optimal, brisk, rapid, or very rapid when measured in pounds or kilograms per week or month. Add current weight to see whether the rate is also high as a percentage of body weight.

How to read the band A steady pace is usually easier to maintain than a very rapid drop. Faster loss can raise the chance of muscle loss, gallstones, dehydration, and nutritional gaps, especially if appetite is very low or side effects make eating difficult.

Quick pace examples

Weight lost Unit / period

Current body weight (optional) Weight unit

Result

Minimal pace

Use the result as a dose-stage and habit-review prompt rather than a safety alarm.

Rate per week: 0 lbs; 0 kg/week
Monthly equivalent: 0 lbs; 0 kg/month
Body-weight pace: Not set; Add current weight for a body-weight percentage check
Safety band: Minimal

Minimal pace Your weight loss pace is very slow or stagnant. This is not dangerous but may indicate the medication is not reaching full effect yet, or dietary changes could be beneficial.

Recommendations

-Consider speaking with your clinician about dose optimisation or dietary adjustments
-Ensure you are on the therapeutic maintenance dose

Review item	Why it matters on GLP-1 medication
Minimal pace	Confirm the dose stage and how long you have been at that dose
Minimal pace	Review appetite change, calorie intake, adherence, sleep, and activity before assuming the medication is ineffective

Typical planning range

Many clinicians review gradual loss around 1-2 lbs per week as a general weight-management target, while GLP-1 users also need to watch percentage of body weight, dose stage, symptoms, protein intake, hydration, and resistance training. Losses above 2.5 lbs per week or above 1% of body weight per week deserve closer review.

Dose schedule calculator

GLP-1 titration calendar for labelled dose schedules Build a dated Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, or Rybelsus dose schedule from a first-dose date, then model clinician-directed holds or a lower selected maintenance dose.

Medication First dose date Clinician-directed hold at each step Planned target dose

Start-date shortcuts

Select a medication and start date Choose your medication and first injection date to generate a titration schedule.

Half-life and washout calculator

Estimate how much GLP-1 medication remains after the last dose, compare semaglutide and tirzepatide half-life timing, and see the usual washout milestones used to discuss Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, and Rybelsus.

Educational pharmacokinetic model This first-order elimination model explains timing concepts such as half-life, steady state, and washout. It does not decide when to stop, restart, switch, combine, or change a prescribed medicine.

Quick scenarios

Medication Days after last dose

Result

6.3% remaining after day 28

About 93.7% is eliminated under a simple first-order model for Wegovy (semaglutide 2.4 mg).

168h

Half-life

7 days

Half-life (days)

35 days

To steady state

30.3 days

95% eliminated

50%

Remaining at next scheduled dose

Concentration after stopping (Wegovy)

Day 0

100%

Day 7

50%

Day 14

25%

Day 21

12.5%

Day 28

6.3%

Day 35

3.1%

Day 42

1.6%

Selected checkpoint	6.3% remaining after 28 days
Elimination half-life	168 hours (7 days)
Steady-state reached (≈5 × t½)	35 days after starting
95% eliminated after stopping	30.3 days
99% eliminated after stopping	46.5 days
Usual dosing interval residual	50% remains after 7 days

Washout milestone	Remaining amount	Approximate timing
50% eliminated	50% remaining	7 days
75% eliminated	25% remaining	14 days
90% eliminated	10% remaining	23.3 days
95% eliminated	5% remaining	30.3 days
97% eliminated	3% remaining	35.4 days
99% eliminated	1% remaining	46.5 days

Clinical note First GLP-1 approved for chronic weight management in non-diabetic adults (2021).

Protein target calculator

Reference weight unit

Goal or reference weight (kg) Activity level Eating occasions per day

Protein already eaten today (g, optional) Resistance training this week

Use extra caution if any apply

Nausea, vomiting, or food aversion Constipation or reflux Very low appetite or skipped meals Kidney disease or renal diet advice

How to choose the weight input

Use your goal or reference weight if you are losing a large amount of weight and want a more practical protein target. If you do not have a goal yet, use your current weight and sense-check the result with your clinician or dietitian.

Protein target

105–120 g per day

Based on 75 kg, moderate (3–5 days/week), and 4 eating occasions.

Daily midpoint: 113 g
Per eating occasion: 26–30 g
Target multiplier: 1.4–1.6 g/kg
Reference weight used: 75 kg
Protein still left today: 105–120 g; 0% of the lower daily target covered.

Daily protein range	105–120 g
Per-eating-occasion target (4/day)	26–30 g
Reference body weight used	75 kg
Activity level	Moderate (3–5 days/week)
Multiplier (g / kg reference weight)	1.4–1.6
Remaining protein gap today	105–120 g

How to use this target Moderate exercisers on GLP-1 therapy benefit from 1.4–1.6 g/kg to support both muscle preservation and workout recovery.

Muscle-preservation context

One or two resistance sessions help, but a consistent plan is usually better for lean-mass retention.

Today's protein gap

Use the remaining gap to choose a meal, snack, or shake that is realistic today.

If appetite is low

Start by securing 26–30 g at your first eating occasion, then use high-protein yoghurt, eggs, shakes, soups, or soft foods to fill the rest of the day. If nausea, vomiting, or constipation is stopping you from eating enough, ask your prescriber or a registered dietitian to review your plan.

US GLP-1 cost calculator

US GLP-1 affordability planner Compare the current low-end published routes for Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, and Rybelsus by indication, dose stage, and pricing scenario before you call the pharmacy or insurer.

What are you pricing?

Pricing scenario Dose stage Spotlight brand

All amounts are shown in US dollars because the manufacturer programmes and coverage notes on this page are US-specific. Formatting follows your saved locale preference, but the underlying pricing references do not convert into other currencies or health systems.

Coverage reality check

This view uses current manufacturer-published savings or self-pay routes when they exist. Eligibility differs by brand, dose, insurance status, and refill timing.

Scope

This planner compares US brand-name pricing references and published savings routes for the included medicines. It does not price compounded products, telehealth membership fees, needle or sharps costs, or non-US pharmacy pathways.

Why plans differ

Coverage for obesity-label GLP-1 therapy still varies widely by employer plan, prior authorisation rules, and pharmacy channel.

Some brands still only publish covered-plan help 3 brands in this view do not have a broad published official cash-pay route, so the comparison table keeps the list-price reference visible and flags those rows for manual follow-up.

Lowest published monthly route for the typical maintenance view

$349.00

Wegovy · 2.4 mg pen · Official cash or manufacturer programme

Current standard self-pay pen price for the maintenance dose.

Published routes

brands with a current figure for this scenario

Monthly spread

$50.00

gap between the lowest and highest priced published route

Savings vs list

$1,000.00

lower than the current list-price reference for the cheapest route

Dose stage

Typical maintenance view

starter, maintenance, or highest published tier

Monthly cost comparison chart

This chart shows the current monthly route for each priced brand in the selected scenario. The highlighted bar follows the brand you are focusing on so you can see where it sits relative to the rest of the market.

Side-by-side comparison

Each row reflects the currently selected indication, pricing scenario, and dose stage. Use the list-price reference column to see how far the published route sits below the brand's baseline price.

Brand	Selected route	Monthly	Annual	List ref.	Coverage context
Wegovy semaglutide 2.4 mg · Weekly injection Weight	2.4 mg pen Published estimate	$349.00	$4,188.00	$1,349.00	Commercial coverage can bring Wegovy down to about $25 per month, while current self-pay pricing is dose-based and time-limited for the first two starter fills.
Ozempic semaglutide 0.5–2 mg · Weekly injection Diabetes	1 mg Published estimate	$349.00	$4,188.00	$1,027.51	Commercial coverage can bring Ozempic down to about $25 per month, and current self-pay pricing is lower for starter fills than for ongoing doses.
Zepbound tirzepatide 5–15 mg · Weekly injection Weight	5 mg Published estimate	$399.00	$4,788.00	$1,086.37	Commercial coverage can bring the pen down to about $25 per month, while self-pay KwikPen or vial pricing depends on dose and refill timing.
Mounjaro tirzepatide 5–15 mg · Weekly injection Diabetes	5 mg No published cash route	No published route	No published route	$1,112.16	The current official route is a covered-plan savings card for eligible commercial insurance users; Lilly does not publish a broad uninsured Mounjaro self-pay price like the Zepbound pathway.
Rybelsus oral semaglutide 14 mg · Daily oral tablet Diabetes	7 mg/day No published cash route	No published route	No published route	$997.58	The current published offer is a commercially insured copay card, not a broad official cash-pay route.
Saxenda liraglutide 3 mg · Daily injection Weight	3 mg/day No published cash route	No published route	No published route	$1,349.02	The current published savings route is a commercial-insurance card; there is no broad official cash-pay price published like the newer Wegovy and Zepbound programmes.

Dose-tier detail for Wegovy

This table keeps every captured dose visible so you can see where a starter fill, maintenance fill, or highest published tier changes the planning number for the highlighted brand.

Dose	Frequency	Monthly	Annual	Planning note
0.25 mg pen Starter	Weekly	$199.00	$2,388.00	Introductory self-pay offer for up to two monthly fills at 0.25 mg or 0.5 mg before the standard self-pay pen price applies.
0.5 mg pen Starter	Weekly	$199.00	$2,388.00	Introductory self-pay offer for up to two monthly fills at 0.25 mg or 0.5 mg before the standard self-pay pen price applies.
1 mg pen	Weekly	$349.00	$4,188.00	Current standard self-pay pen price after the introductory starter period.
1.7 mg pen	Weekly	$349.00	$4,188.00	Current standard self-pay pen price after the introductory starter period.
2.4 mg pen Maintenance	Weekly	$349.00	$4,188.00	Current standard self-pay pen price for the maintenance dose.

Before you switch brands based on cost alone US pricing references only. Out-of-pocket cost depends on indication, formulary status, prior authorisation, pharmacy channel, and whether you qualify for the current manufacturer programme. If you are comparing weight-loss and diabetes-label brands for your own treatment plan, review the cost assumptions with your prescriber, insurer, and dispensing pharmacy before making a medication change.

GLP-1 calculator FAQ

Can this page tell me whether I should start a GLP-1 medication?

No. It can organise label criteria, comparison points, projections, and safety questions, but a licensed clinician must decide whether a GLP-1 or GIP/GLP-1 medicine is appropriate for your medical history.

Why are there separate tools for projection, rate, protein, and cost?

GLP-1 planning has several different jobs. Trial-average projections do not prove your personal response, weight-loss rate checks focus on safety signals, protein targets help protect lean mass during appetite suppression, and cost estimates depend on indication, dose stage, insurance, and pharmacy channel.

How often should I recheck these results?

Recheck when your dose changes, symptoms change, weight-loss pace accelerates or stalls, your clinician changes the plan, or pricing and coverage information changes. Use current labels and clinician guidance because GLP-1 evidence and access rules continue to evolve.

About this calculator

Health estimate Reviewed 2 May 2026 Updated 2 May 2026

Editorial responsibility

Calcipedia editorial team

This page is maintained against the site trust model for its topic and updated when formulas, sources, or guidance materially change.

Formula provenance

The methodology summary explains the formula family in use, and the source list points to the primary or authoritative references checked for this topic.

Methodology

This master page does not combine all GLP-1 decisions into a single medical score. It maps broad GLP-1 calculator intent to narrower calculators and explains the evidence boundaries behind common outputs. Weight-loss estimates should use published trial-average percentages, medication comparisons should keep indication and route context visible, dose schedules should follow label and prescriber context, and cost or nutrition estimates should expose assumptions rather than presenting guaranteed outcomes.

Limitations

This page is a navigation and interpretation layer, not a personal medical assessment or treatment recommendation.
Sibling calculators may use different evidence models because weight projection, medication comparison, dosing, cost, eligibility, protein, half-life, and weight-loss-rate questions are not interchangeable.
Published trial averages do not predict one person's response, side effects, discontinuation risk, insurance coverage, access, or long-term regain pattern.
FDA approvals, warnings, product labels, supply status, and payer rules can change; users should verify current prescribing information with a clinician or pharmacist.
No redirects or consolidation of sibling GLP-1 calculators should occur until a named medical reviewer has approved the clinical and SEO implications.

Disclaimer

This page is for educational planning only and is not medical advice. It does not diagnose, prescribe, recommend a medication, set a dose, manage side effects, or replace care from a licensed clinician. Do not start, stop, switch, restart, or change GLP-1 medication based on this page or any calculator output.

Primary health sources

FDA — Wegovy approval for chronic weight management — FDA announcement describing semaglutide 2.4 mg approval for chronic weight management and important label context for obesity-treatment planning.
FDA — Zepbound approval for obstructive sleep apnea — FDA announcement documenting a current tirzepatide label expansion, useful for reminding users that GLP-1 and GIP/GLP-1 label context changes over time.
PubMed — Once-weekly semaglutide in adults with overweight or obesity — PubMed record for STEP 1, a pivotal semaglutide 2.4 mg obesity trial frequently used to anchor Wegovy weight-loss projection context.
PubMed — Tirzepatide once weekly for the treatment of obesity — PubMed record for SURMOUNT-1, a pivotal tirzepatide obesity trial commonly used for Zepbound weight-loss projection context.
PubMed — Tirzepatide as compared with semaglutide for the treatment of obesity — PubMed record for SURMOUNT-5, the direct tirzepatide-versus-semaglutide obesity comparison that helps contextualize medication-comparison calculators.

Change notes

Health change note: the formula, reference ranges, source set, disclaimer, and safety guidance for this calculator were last reviewed on 2026-05-02. Report a correction at contact@calcipedia.org; substantive source or guidance changes refresh both the reviewed date and the updated date shown on the page.

See our calculation methodology and editorial standards, plus the editorial contact route, for how this estimate is produced and corrected.

← All Weight Loss Medication calculators

GLP-1 Calculator

GLP-1 calculator: choose the right GLP-1 tool for weight loss, dose, cost, eligibility

This GLP-1 calculator master page is built for broad GLP-1 calculator and GLP-1 calculators intent. This page also explains the main assumptions behind the glp-1 calculator result, highlights the supporting figures shown by the calculator, and helps the reader use the estimate without overstating what a quick online tool can prove.

What this GLP-1 calculator master page is for

People search for a GLP-1 calculator for different reasons. One person may want a trial-average weight-loss projection, another may want to compare Wegovy and Zepbound, and someone else may be trying to understand a dose schedule, monthly cost, eligibility, medication half-life, or protein target while appetite is lower. A single generic GLP1 calculator cannot safely answer all of those questions with one number.

This master page is intentionally additive. It gives broad GLP-1 calculator users a clear starting point and points them toward the narrower GLP-1 calculators that already own the detailed long-tail intent. That keeps a broad hub useful without diluting specialist pages such as the GLP-1 weight loss calculator, GLP-1 medication comparison calculator, GLP-1 dose schedule calculator, GLP-1 eligibility calculator, GLP-1 cost calculator, GLP-1 protein calculator, GLP-1 half-life calculator, and GLP-1 weight loss rate calculator.

Which GLP-1 calculator should you use?

Use the GLP-1 weight loss calculator when your main question is how published trial-average percentages translate into pounds or kilograms over time. Use the GLP-1 medication comparison calculator when the real question is brand context, route, label status, and the difference between obesity-label and diabetes-label products. Those two tools answer related but different questions, so this page keeps them separate instead of treating weight-loss projection and medication selection as the same task.

Use the GLP-1 dose schedule calculator for titration timing and appointment planning, the GLP-1 eligibility calculator for a structured discussion of common eligibility factors, and the GLP-1 cost calculator when affordability or coverage questions are driving the search. Use the GLP-1 protein calculator when reduced appetite makes nutrition planning harder, the GLP-1 half-life calculator for medication-timing context, and the GLP-1 weight loss rate calculator when you need to interpret pace rather than total projected loss.

Why broad GLP-1 calculators need medical boundaries

GLP-1 and GIP/GLP-1 medicines are prescription treatments with indications, contraindications, titration schedules, adverse-effect monitoring, supply considerations, and access rules that vary by product and patient. A calculator can organize published evidence and make planning numbers easier to read, but it cannot decide whether semaglutide, tirzepatide, liraglutide, or another option is appropriate for you.

That boundary matters most when a broad GLP calculator tries to combine eligibility, weight loss, cost, dosing, and medication choice in one screen. The more clinical factors a tool combines, the easier it is for a user to mistake a planning estimate for a recommendation. This page is structured to avoid that mistake: it routes you to the right calculator, explains what each output can and cannot mean, and keeps the not-medical-advice disclaimer visible.

Source review and medical reviewer status

The source set for this master GLP-1 calculator was reviewed on 2026-05-02 against accessible FDA and PubMed sources. Because GLP-1 labels, warnings, shortages, prices, and access rules can change, this page treats current-source review as part of the calculator output rather than a background detail.

No named medical reviewer has approved redirect consolidation for the sibling GLP-1 calculators. That is why the existing dose schedule, half-life, eligibility, medication comparison, weight-loss projection, weight-loss-rate, protein, and cost calculators remain live and independently indexable.

How the sibling GLP-1 calculators fit together

The sibling GLP-1 calculators are designed to answer specific questions. Weight-loss projection pages use trial averages; comparison pages keep brand, molecule, route, indication, and trial context visible; dose-schedule pages focus on timing rather than outcomes; cost pages focus on price and coverage assumptions; and nutrition pages focus on protein planning during reduced appetite. They should be linked together, not merged into one overconfident answer.

That is why this master page does not replace sibling long-tail pages. Broad GLP-1 calculators intent belongs here, while narrower primary keywords stay with the pages that answer those exact questions. This prevents users who need a dose schedule or medication comparison from landing on a generic weight-loss-only page, and it prevents broad users from being pushed straight into a clinical decision they did not ask the calculator to make.

Worked example: choosing a calculator from a broad GLP-1 search

Suppose someone searches for GLP-1 calculator because they have heard about Wegovy, Zepbound, Ozempic, and Mounjaro but are not sure what they actually need. If their question is 'How much weight might a trial-average result represent for my starting weight?', the right next step is the weight-loss projection calculator. If their question is 'Which medication category am I comparing, and which rows are obesity-label versus diabetes-label?', the medication comparison calculator is a better fit.

If the same person then asks whether they appear to meet common eligibility factors, whether a dose increase lines up with a follow-up visit, or what monthly out-of-pocket cost could look like, those are separate calculator tasks. Splitting the journey this way is less flashy than one giant result, but it is more honest for a medical topic because each output stays tied to the evidence and assumptions behind it.

What this page cannot tell you

This page cannot tell you whether you should start a GLP-1 medication, stop one, switch brands, change dose, extend a titration step, combine treatments, or ignore side effects. It also cannot decide whether a medication is appropriate with pregnancy, gallbladder disease, pancreatitis history, kidney disease, gastroparesis, diabetes treatment, insulin use, eating-disorder history, thyroid cancer risk, or any other clinical factor.

Use the calculators as planning aids for a conversation with a licensed clinician. Do not use them as a prescription decision, diagnosis, treatment plan, side-effect triage tool, emergency guide, or substitute for the current label and professional medical judgement.

Frequently asked questions

What is the best GLP-1 calculator to start with?

Start with this GLP-1 calculator master page if your question is broad. It routes you to the specific calculator that matches your intent: weight-loss projection, medication comparison, dose schedule, eligibility, cost, protein planning, half-life timing, or weight-loss-rate interpretation.

Is this master page replacing the other GLP-1 calculators?

No. This is an additive master page for broad GLP-1 calculator and GLP-1 calculators searches. The narrower sibling calculators keep their own long-tail focus because medication comparison, dose scheduling, cost, eligibility, protein planning, half-life, and weight-loss projection are different tasks.

Can a GLP-1 calculator tell me which medication to take?

No. A calculator can organize evidence, label context, trial averages, and planning assumptions, but it cannot choose a prescription medication for you. GLP-1 medication choice should be made with a licensed clinician who knows your diagnosis, risks, goals, current medicines, and monitoring needs.

Why do GLP-1 weight-loss calculators use trial averages?

Trial averages are more reliable than anecdotes, but they are still population summaries. Individual response can be higher or lower because dose reached, tolerability, adherence, baseline health, diet, activity, side effects, and treatment duration all matter.

Are Ozempic and Wegovy handled the same way in GLP-1 calculators?

They both contain semaglutide, but they are not the same planning row once indication, dose, label, and study population are considered. A careful GLP-1 calculator keeps diabetes-label and obesity-label contexts visible instead of treating brand names as interchangeable.

Are Mounjaro and Zepbound the same in a calculator?

They both contain tirzepatide, but they sit in different label and access contexts. A calculator may show them together for comparison, but it should still mark the indication and evidence context so the output is not mistaken for direct substitution advice.

Can I use a GLP-1 calculator for dosing decisions?

Use a dose-schedule calculator only to understand timing and questions to raise with your prescriber. Do not change, skip, restart, or accelerate a GLP-1 dose based on a calculator.

Does this page provide medical advice?

No. This page and the linked GLP-1 calculators are educational planning tools only. They do not provide medical advice, diagnosis, treatment, prescribing guidance, side-effect triage, or emergency instructions.

Also in Weight Loss Medication

🇺🇸 GLP-1 Cost Calculator 🇺🇸 GLP-1 Dose Schedule Calculator 🇺🇸 GLP-1 Eligibility Calculator GLP-1 Half Life Calculator GLP-1 Medication Comparison Calculator GLP-1 Protein Calculator GLP-1 Weight Loss Calculator GLP-1 Weight Loss Rate Calculator

🇺🇸 Browse all United States calculators

GLP-1 Calculator🇺🇸

Plan the whole GLP-1 conversation, not just one number

Specialist GLP-1 calculators

Eligibility and clinical review screen

Medication comparison calculator

Zepbound

Side-by-side comparison sheet

Dose pathway for Zepbound

Weight-loss projection calculator

187.22 lbs

Weight-loss rate safety calculator

Minimal pace

Dose schedule calculator

Half-life and washout calculator

6.3% remaining after day 28

Protein target calculator

105–120 g per day

US GLP-1 cost calculator

$349.00

Monthly cost comparison chart

Side-by-side comparison

Dose-tier detail for Wegovy

GLP-1 calculator FAQ

GLP-1 calculator: choose the right GLP-1 tool for weight loss, dose, cost, eligibility

What this GLP-1 calculator master page is for

Which GLP-1 calculator should you use?

Why broad GLP-1 calculators need medical boundaries

Source review and medical reviewer status

How the sibling GLP-1 calculators fit together

Worked example: choosing a calculator from a broad GLP-1 search

What this page cannot tell you

More from nearby categories

GLP-1 Weight Loss Calculator

GLP-1 Medication Comparison Calculator

GLP-1 Dose Schedule Calculator🇺🇸

GLP-1 Eligibility Calculator🇺🇸